Diagnostic companies partnering with drug developers can make for an attractive investment segment.
A recap of Xconomy's recent event, "Boston's War on Cancer."
Boston's War on Cancer examines the state and direction of cancer therapy research.
Millennium CEO Dr. Deborah Dunsire talks to the Fool's Ralph Casale about the state of the industry.
Notes from Xconomy's "War on Cancer" biotechnology forum.
Roche buys out second-generation sequencer 454 Life Scienes.
Wherefore is there Daylight Saving Time?
A look at Beckman-coulter's acquisition of Biosite.
New diagnostics products make for a bright 2007.
A win for all involved.
The medical equipment manufacturer has both causes for concern and reasons to be positive.
Abbott trades its medical diagnostics segment for cold hard cash.
Glaxo's an all-around winner for the year to come.
CAPS players rate the best companies supporting the biotechnology and pharmaceutical industries.
Show this Fool the money.
Buybacks aren't bad, but cash is king.
Fundamental indexing offers a new twist on the tried-and-true strategy of index investing.
How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals.
Few investors have been as successful as The Mummy.
Learn to conquer your inner Mr. Hyde.